



ASX RELEASE (3 MARCH 2020)

Production commenced to support 6,000 Australian Patients

First ASX Listed Company to Achieve Aims of Narcotic Drugs Act with 100% In-House Capability

THC Global Group Limited (**THC Global** or the **Company**) (ASX:THC) today announces it has received an expanded commercial cultivation permit from the Australian Office of Drug Control (ODC), and has commenced production towards supply of medicinal cannabis medicines to an initial 6,000 Australian patients.

THC Global Group CEO, Ken Charteris, commented: "We are committed to bringing lower costs and higher quality to Australian patients. Our complete control of cannabis biomass, manufacturing, supply, and support will help achieve this. We expect to supply at least an initial 6,000 patients using Canndeo medicinal cannabis on an ongoing basis commencing from Q2 2020. Further Australian patients and global exports will follow."

High Quality Medicinal Cannabis Medicines

THC Global will exercise its new expanded cultivation permit for the Company's Bundaberg cultivation facility ('Bundy'), as well as associated research permits and licence amendments, to support an at least an initial 3,000 patients with 100% Australian medicinal cannabis.

THC Global is concurrently finalising importation of crude cannabis extract for medicine production, and also finalising contract negotiation for cannabis supply from additional licensed and permitted Australian cannabis cultivators. This biomass will be directed towards supporting a minimum additional 3,000 patients.

THC Global has previously received a manufacturing permit for medicinal cannabis, and received a pharmaceutical GMP licence, enabling supply of medicinal cannabis medicines to Australian and international patients from its Southport manufacturing facility.

An announcement by the Australian Minister for Health, The Hon. Greg Hunt MP on 4 January 2018 clarified that medicinal cannabis be made available to Australian patients first as a condition of any export licence. THC Global has discussed export intentions with Australia's Therapeutic Goods Administration (TGA). Export-focused production is expected to commence once adequate supply to Australian patients has been assured.

Patient Focused Medicines

THC Global will supply medicinal cannabis under the Canndeo brand. Supply will be direct to pharmacies, clinics and hospitals, meeting the requirements of the Narcotic Drugs Act and Regulations.

THC Global has established CanndeoCare™ for support of doctors and health care professionals. CanndeoCare™ will provide information on prescribing as permitted by the Therapeutic Goods Act from a team of qualified healthcare professionals focused on supporting responsible and legal prescribing of medicinal cannabis.

Improving Australian Patient Outcomes

A commercial cultivation permit, manufacturing permit and pharmaceutical GMP licence are prerequisites for Australian cannabis medicines to have valid data generation in study and clinical trials.

THC Global is currently in discussion and anticipates commencement of trials commencing from Q3 2020, with first trials focusing on Australian patient groups with high CBD dosage requirements. THC Global's Southport facility is licensed for the production and supply of clinical trial material.



For further information, please contact:



Ken Charteris
Chief Executive Officer
e: ceo@thc.global

Henry Kinstlinger
Company Secretary
e: corporate@thc.global
p: +61 2 8644 0601

Sonny Didugu
Investors & Media
e: media@thc.global
p: +61 2 8644 0601

ASX release authorised by THC Global's Management Committee – the Chairman, Deputy Chairman, and CEO.

THC Global Group Limited (ASX: THC) thc.global

THC Global is a diversified global cannabis company with primary operations in Australia and Canada. THC Global is the first ASX listed entity to fully own and operate commercial medicinal cannabis production facilities under Australia's cannabis regulations. THC Global's Southport Facility is one of the largest pharmaceutical GMP cannabis manufacturing facilities in the world. THC Global also owns and operates Crystal Mountain, a profitable, fast growing hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sector in North America, and Europe.